Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.
Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial. The ALSYMPCA trial looked at radium-223 dichloride in patients with bone metastases from prostate cancer.
Vogelzang recently presented a study at the 2013 American Urological Association (AUA) Annual Meeting that showed reduction in the use of morphine, reduction in the need for radiation, and improvement in quality of life. Quality of life was measured using a standard method.
At the 2013 American Society of Clinical Oncology (ASCO) Meeting, Vogelzang presented a study looking at the effect on patients who have been treated with chemotherapy. The study analyzed what radium-223 did to the patients' blood counts and found that it had little effect.